EXEL
Exelixis, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 180.49M | $9.80B | +5 | −5 |
| Q1 2026 | 143 | -1 | 180.18M | $7.73B | +4 | −6 |
| Q4 2025 | 143 | +1 | 192.52M | $8.44B | +2 | — |
| Q3 2025 | 20 | -1 | 116.93M | $4.83B | — | −2 |
| Q2 2025 | 19 | +2 | 115.09M | $5.07B | +2 | — |
| Q1 2025 | 14 | -1 | 52.64M | $1.94B | +1 | −2 |
| Q4 2024 | 15 | +1 | 49.00M | $1.63B | +1 | — |
| Q3 2024 | 13 | 0 | 34.27M | $889.30M | — | — |
| Q2 2024 | 13 | — | 31.74M | $712.85M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 15.16M | — | $340.71M | 0.6% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 5.17M | — | $116.11M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 5.17M | — | $116.11M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 3.28M | — | $73.43M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 3.28M | — | $73.43M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 3.28M | — | $73.43M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 2.79M | — | $62.67M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 1.95M | — | $43.81M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 1.95M | — | $43.81M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 1.20M | — | $26.91M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 564.07K | — | $12.67M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 564.07K | — | $12.67M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 544.66K | — | $12.24M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Millennium Management ✦ | 385.69K | — | $8.67M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Wellington Management ✦ | 369.88K | — | $8.31M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Wellington Management ✦ | 369.88K | — | $8.31M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 253.20K | — | $5.69M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 36.25K | — | $814,627 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Marshall Wace ✦ | 35.64K | — | $800,921 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 692 holders, 256.72M shares, $10.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 9.81K sh · $526,512
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
5.6% of class · View original SEC filing ↗